Credit: Pfizer. Patients should be selected for treatment based on the presence of HRR gene mutations. The Food and Drug Administration (FDA) has approved Talzenna ® (talazoparib), in combination with ...
New data suggest that olaparib without ADT could be a reasonable treatment strategy in selected patients with high-risk prostate cancer that recurs after radical prostatectomy. Olaparib monotherapy ...
The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior ...
Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US). This is an ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — The addition of niraparib to abiraterone acetate and prednisone improved multiple outcomes for ...
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with ...
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated ...
Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first precision medicine combo for patients with BRCA2-mutated metasta | Akeega, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback